ASS1 and hepatocellular carcinoma: Second, arginine metabolic enzyme ASS1 and the pyrimidine synthetic pathway not only can serve as emerging biomarkers for post-surgery recurrence assessment, but can also represent a potential therapeutic option targeting the abnormal metabolism of HCC.